These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 2118421)

  • 21. In vitro modulatory effects of interleukin-3 on macrophage activation induced by interleukin-2.
    Lissoni P; Pittalis S; Brivio F; Tisi E; Rovelli F; Ardizzoia A; Barni S; Tancini G; Giudici G; Biondi A
    Cancer; 1993 Mar; 71(6):2076-81. PubMed ID: 8443757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patterns of cytokines released by peripheral blood leukocytes of normal donors and cancer patients during interleukin-2 activation in vitro.
    Dupere S; Obiri N; Lackey A; Emma D; Yannelli J; Orr D; Birch R; O'Connor TE
    J Biol Response Mod; 1990 Apr; 9(2):140-8. PubMed ID: 2111374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced expression of cytokines may play a fundamental role in the mechanisms of immunologically mediated recurrent spontaneous abortion.
    Shaarawy M; Nagui AR
    Acta Obstet Gynecol Scand; 1997 Mar; 76(3):205-11. PubMed ID: 9093132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cellular immunity in pregnancy-induced hypertensive diseases].
    Schröcksnadel H; Herold M; Steckel-Berger G; Fuchs D; Wachter H; Dapunt O
    Geburtshilfe Frauenheilkd; 1992 Oct; 52(10):592-5. PubMed ID: 1294433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new approach to adoptive immunotherapy of cancer using tumorcytotoxic macrophages grown from peripheral blood monocytes.
    Andreesen R; Scheibenbogen C; Brugger W; Krause S; Leser HG; Kopf S; Engler H; Schümichen C; Löhr GW
    Cancer Detect Prev; 1991; 15(5):413-21. PubMed ID: 1751953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between pretreatment serum levels of neopterin and response to interleukin-2 immunotherapy in cancer patients.
    Lissoni P; Barni S; Ardizzoia A; Scardino E; Tancini G; Viganò MG
    J Biol Regul Homeost Agents; 1995; 9(1):21-3. PubMed ID: 8553904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluctuations of plasma beta 2-microglobulin, soluble interleukin 2 receptor and interferon-gamma concentrations after adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells.
    Giannella G; Pelosi-Testa E; Carlini P; Habetswallner D; Montesoro E; Camagna A; Calzini V; Ruggeri EM; Arena MG; Masciulli R
    Immunobiology; 1989 Feb; 178(4-5):305-15. PubMed ID: 2497064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytokine induction of neopterin production.
    Henderson DC; Sheldon J; Riches P; Hobbs JR
    Clin Exp Immunol; 1991 Mar; 83(3):479-82. PubMed ID: 1825941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
    Goldstein D; Sielaff KM; Storer BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC
    J Natl Cancer Inst; 1989 Jul; 81(14):1061-8. PubMed ID: 2472488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin 2 protects hairy leukemic cells from lymphokine-activated killer cell-mediated cytotoxicity.
    Reiter Z; Taylor MW
    Cancer Res; 1993 Aug; 53(15):3555-60. PubMed ID: 7687924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunomodulatory effects of recombinant interleukin-3 treatment on human alveolar macrophages and monocytes.
    Thomassen MJ; Antal JM; Connors MJ; McLain D; Sandstrom K; Meeker DP; Budd GT; Levitt D; Bukowski RM
    J Immunother Emphasis Tumor Immunol; 1993 Jul; 14(1):43-50. PubMed ID: 8399069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients.
    Witt PL; Ritch PS; Reding D; McAuliffe TL; Westrick L; Grossberg SE; Borden EC
    Cancer Res; 1993 Nov; 53(21):5176-80. PubMed ID: 8221654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Changes of serum 2',5'-oligoadenylate synthetase activity and neopterin during interferon treatment for chronic hepatitis C].
    Daito K; Suou T; Kawasaki H
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):981-5. PubMed ID: 7563914
    [No Abstract]   [Full Text] [Related]  

  • 34. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
    Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
    Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of human monocyte function against Candida albicans by autologous IL-2-induced lymphokine-activated killer cells.
    Wei S; Serbousek D; McMillen S; Blanchard DK; Djeu JY
    J Immunol; 1991 Jan; 146(1):337-42. PubMed ID: 1898605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Further evidence for lymphokine overproduction in severe aplastic anemia.
    Hinterberger W; Adolf G; Aichinger G; Dudczak R; Geissler K; Höcker P; Huber C; Kalhs P; Knapp W; Köller U
    Blood; 1988 Jul; 72(1):266-72. PubMed ID: 3134066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
    Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
    Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Release of cytokines during generation of lymphokine-activated killer (LAK) cells by IL-2.
    Limb GA; Meager A; Woolley J; Wadhwa M; Biggerstaff J; Brown KA; Wolstencroft RA
    Immunology; 1989 Dec; 68(4):514-9. PubMed ID: 2514140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combinational IL-2/IL-15 induction does not further enhance IL-15-induced lymphokine-activated killer cell cytotoxicity against human leukemia/lymphoma cells.
    Ozdemir O; Savaşan S
    Clin Immunol; 2005 Jun; 115(3):240-9. PubMed ID: 15893691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.